epilepsy

Phase 3 data presented at AAN 2026 show azetukalner nearly halved seizure frequency in treatment-resistant focal epilepsy, with 38% of long-term patients achieving over a year of seizure freedom.

Early-phase data in 81 children with Dravet syndrome showed large seizure reductions and manageable safety issues as a phase 3 trial moves ahead.